Doxazosin
- Generic Name
- Doxazosin
- Brand Names
- Cardura
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N5O5
- CAS Number
- 74191-85-8
- Unique Ingredient Identifier
- NW1291F1W8
- Background
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
- Indication
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus
CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders
- Conditions
- Posttraumatic Stress DisorderAlcohol Use Disorders
- Interventions
- Drug: placebo
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 144
- Registration Number
- NCT02500602
- Locations
- 🇺🇸
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States
Optimum Treatment for Drug-Resistant Hypertension
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- University of Cambridge
- Target Recruit Count
- 348
- Registration Number
- NCT02369081
- Locations
- 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧University of Birmingham, Birmingham, United Kingdom
🇬🇧University of Cambridge - Addenbrookes Hospital, Cambridge, United Kingdom
DOXAZOSIN FOR PTSD
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT02308202
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02266537
A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- San Francisco Veterans Affairs Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01959022
- Locations
- 🇺🇸
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 43
- Registration Number
- NCT01953432
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
Alpha-Blockers in Allergic Rhinitis (MAN 01)
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 17
- Registration Number
- NCT01946035
- Locations
- 🇬🇧
Brian Lipworth, Dundee, United Kingdom
Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
- Conditions
- Smoking
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Yale University
- Target Recruit Count
- 35
- Registration Number
- NCT01730846
- Locations
- 🇺🇸
Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT01678313
- Locations
- 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
- Conditions
- Bladder Outlet Obstruction
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 395
- Registration Number
- NCT01661621
- Locations
- 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.